Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

We present an integrated approach to derive multimodal MRI markers of cognition that can be transdiagnostically linked to psychopathology. This demonstrates that the predictive ability of neural ...

This study illustrates a valuable application of BID-seq to bacterial RNA, allowing transcriptome-wide mapping of pseudouridine modifications across various bacterial species. The evidence presented ...